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Background: Isolation of extracellular vesicles from plasma is a challenge due to the presence of proteins and
lipoproteins. Isolation of vesicles using differential centrifugation or density-gradient ultracentrifugation
results in co-isolation of contaminants such as protein aggregates and incomplete separation of vesicles from
lipoproteins, respectively.
Aim: To develop a single-step protocol to isolate vesicles from human body fluids.
Methods: Platelet-free supernatant, derived from platelet concentrates, was loaded on a sepharose CL-2B
column to perform size-exclusion chromatography (SEC; n3). Fractions were collected and analysed by
nanoparticle tracking analysis, resistive pulse sensing, flow cytometry and transmission electron microscopy.
The concentrations of high-density lipoprotein cholesterol (HDL) and protein were measured in each
fraction.
Results: Fractions 912 contained the highest concentrations of particles larger than 70 nm and platelet-
derived vesicles (46%96 and 61%92 of totals present in all collected fractions, respectively), but less than 5%
of HDL and less than 1% of protein (4.8%91 and 0.65%90.3, respectively). HDL was present mainly in
fractions 1820 (32%92 of total), and protein in fractions 1921 (36%92 of total). Compared to the starting
material, recovery of platelet-derived vesicles was 43%923 in fractions 912, with an 8-fold and 70-fold
enrichment compared to HDL and protein.
Conclusions: SEC efficiently isolates extracellular vesicles with a diameter larger than 70 nm from platelet-free
supernatant of platelet concentrates. Application SEC will improve studies on the dimensional, structural and
functional properties of extracellular vesicles.
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T
he scientific and clinical interest in plasma-derived
vesicles is tremendous, since these vesicles may
contain clinically relevant information (15). Iso-
lation of vesicles from plasma with good recovery and
without contamination of proteins and lipoproteins,
however, is a challenge. Thus far, most isolation protocols
are based on differential centrifugation. After removal
of cells in the first low-speed centrifugation step, vesicles
are isolated using centrifugal accelerations of 19,000
100,000 g (6). Unfortunately, protein aggregates are gene-
rated at high velocities of  100,000 g, (79) and vesicles
may clump. Isolation of vesicles from plasma is further
hampered by the viscosity and density of plasma, and by
the presence of lipoprotein particles with a density and
diameter similar to the extracellular vesicles of in-
terest (6,10,11). Consequently, isolation of vesicles from
plasma or serum by density-gradient ultracentrifugation
results in co-isolation of high-density lipoprotein (HDL),
and isolation of HDL results in co-isolation of vesicles
[as described in the response of Yuana Y. and Nieuwland R.

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urgent need for a simple and fast protocol to isolate
vesicles from human plasma.
In platelet research, two different protocols are com-
monly applied to isolate platelets from platelet-rich
plasma,that is,toreplace theplasmabybuffer.Inonepro-
cedure, platelets are isolated from the plasma by centrifu-
gation and washing (14,15). In the other procedure,
platelets are isolated by size-exclusion chromatography
(SEC),alsoknownas‘‘gelfiltration’’(15,16).SEChasalso
been used previously to isolate vesicles from sera, ascites
and saliva, and was shown to separate vesicles from
proteins (1720). Whether SEC separates vesicles from
HDL, however, has never been investigated. In this study,
we investigate the efficacy of single-step SEC for isolation
of extracellular vesicles from human platelet-free super-
natant of platelet concentrates and we studied the separa-
tion of vesicles by SEC from HDL and proteins.
Material and methods
Platelet concentrates
Platelet concentrates were from Sanquin (Amsterdam,
The Netherlands). Buffy coats from 5 whole blood units
are pooled together with one plasma unit of one of these
donors. Subsequently, this pool was gently centrifuged.
The resulting platelet rich plasma was slowly extracted
using an automated separator via leukocyte reduction
filter to a PVC-citrate storage bag. Platelet concentrates
(n3, 912 days old,B1 leukocyte/310
8 platelets)
were stored with agitation at room temperature until use.
Platelet-depleted plasma
Platelet concentrate (30 mL) was diluted 1:1 with filtered
phosphate-buffered saline [PBS; 1.54 mol/L NaCl, 12.4
mmol/L Na2HPO4, 2.05 mmol/L NaH2PO4, pH 7.4; 0.22
mm filter (Merck chemicals BV, Darmstadt, Germany)].
Next, 12 mL acid citrate dextrose (ACD; 0.85 mol/L
trisodiumcitrate, 0.11 mol/L D-glucose and 0.071 mol/L
citric acid) was added and the suspension was centrifuged
for 20 minutes at 800g, 208C. Thereafter, the vesicle-
containing supernatant was isolated and centrifuged (20
minutes at 1,550 g, 208C) to remove remaining platelets.
This centrifugation procedurewas repeated for 3 cycles, to
ensure complete removal of platelets.
SEC column
Sepharose CL-2B (30 mL, GE Healthcare; Uppsala,
Sweden) was washed with PBS containing 0.32% triso-
diumcitrate (pH 7.4, 0.22 mm filtered). Subsequently, the
tipofa10mLplasticsyringe[BectonDickinson(BD),San
Jose, CA] was stuffed with nylon stocking (20 denier,
Hema,Amsterdam,TheNetherlands),andthesyringewas
stacked with 10 mL washed sepharose CL-2B (Fig. 2) to
create a column with diameter of 1.6 cm and height of
6.2 cm (Fig. 1).
Collection of fractions
Platelet-freesupernatantofaplateletconcentrate(1.5mL)
was loaded on the column, followed by elution with PBS/
0.32% citrate (pH 7.4, 0.22 mm filtered). The eluate was
collected in 26 sequential fractions of 0.5 mL (Fig. 1).
For each fraction, the number of particles was determined
by nanoparticle tracking analysis (NTA), resistive pulse
sensing (RPS) and flow cytometry. In addition, HDL
cholesterol and protein concentrations were measured
for each fraction. Of each fraction,  200 mL was frozen
in liquid nitrogen and stored at 808C for subse-
quenttransmissionelectronmicroscopy(TEM)onthawed
fractions.
Nanoparticle tracking analysis
The concentration and size distribution of particles in
collected fractions was measured with NTA (NS500;
Nanosight, Amesbury, UK), equipped with an EMCCD
camera and a 405 nm diode laser. Silica beads (100 nm
diameter; Microspheres-Nanospheres, Cold Spring, NY)
were used to configure and calibrate the instrument.
Fractions were diluted 101,000-fold in PBS to reduce the
number of particles in the field of view below 200/image.
Of each fraction, 10 videos, each of 30-seconds dura-
tion, were captured with the camera shutter set at 33.31
ms and the camera gain set at 400. All fractions were
Fig. 1. Image of size-exclusion chromatography column. A
10 mL syringe stacked with sepharose CL-2B for isolation of
vesicles from platelet-free supernatant of platelet concentrates.
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ted by custom-made software (MATLAB v.7.9.0.529).
Analysis was performed by the instrument software (NTA
2.3.0.15).
Resistive pulse sensing
The concentration and size distribution of particles was
measuredwithRPS(qNano;IzonScienceLtd,Christchurch,
NewZealand)usinganNP200Ananopore.Thisnanopore
was suitable for the detection of 100400 nm particles.
Samples were measured with 7 mbar pressure, 45 mm
stretch and 0.34 V. Sampleswere analysed for 5 minutes or
until 1,000 vesicleswere counted, whichever came first. To
calibrate sizeand concentration, carboxylatedpolystyrene
beads (Izon Science Ltd) were sonicated for 10 seconds,
diluted in PBS with 0.3 mM sodium dodecyl sulphate and
analysed immediately after dilution.
Flow cytometry
To detect platelet vesicles, 20 mL of each fraction was
incubated for 15 minutes with an antibody against
glycoprotein IIIa (CD61), which is a subunit of the
platelet fibrinogen receptor and also known as integrin
b3, phycoerythrin (PE)-conjugated CD61; 5 mL 1:10
prediluted in PBS/citrate, Pharmingen, San Diego, CA).
IgG1-PE (BD) was used as control antibody. To detect
all vesicles, 20 mL of each fraction was labelled with
lactadherin (fluorescein isothiocyanate-conjugated, 5 mL
1:10 prediluted in PBS/citrate). After incubation, 300 mL
PBS/citrate was added and samples were analysed on a
FACSCalibur (BD, Cellquest version 4.0.2) for 1 minute
at a flow rate of 60 mL min
1. The trigger was set on FSC
at E00, SSC voltage of 329, threshold FSC 30, SSC 0. No
gates were used to determine extracellular vesicles.
Transmission electron microscopy
After thawing, samples from all fractions, both undiluted
and 50-fold diluted in PBS, were subjected to overnight
fixation, in 0.1% final concentration (v/v) paraformalde-
hyde(Electron MicroscopyScience,Hatfield, PA). Then, a
200-mesh formvar and carbon coated copper grid (Elec-
tronMicroscopyScience)wasplacedona10mLdropletto
allow adherence of particles to the grid (7 minutes, room
temperature). Thereafter, the grid was transferred onto
drops of 1.75% uranyl acetate (w/v) for negative stain-
ing. Each grid was studied using a transmission electron
microscope (Fei, Tecnai-12; Eindhoven, the Netherlands)
operated at 80 kV using a Veleta 2,0002,000 side-
mounted CCD camera and Imaging Solutions software
(Olympus, Shinjuku, Tokyo, Japan).
Protein
The protein concentration was determined using a
Bradford protein assay according to the manufacturer’s
instructions (Pierce, Rockford, IL). The absorbance was
measured at 595 nm on a Spectramax Plus (Molecular
Devices, Sunnyvale, CA). In addition, to directly visualize
the relative presence of proteins in the collected fractions,
in a single experiment, 10 mL of each fraction was mixed
with 10 mL 2-fold concentrated reducing sample buffer,
boiled for 5 minutes and loaded on an 816% gradient
gel (BioRad, Hercules, CA). Proteins were stained with
Bio-Safe Coomassie G-250 Stain (BioRad).
Western blot
Proteins from all fractions (800 mL) were precipitated
using trichloroacetic acid (20% final concentration;
Sigma-Aldrich, St. Louis, MO). From each fraction,
equal amounts of protein (4 mg) were dissolved in non-
reducing sample buffer, boiled and loaded on 816%
gradient PAGE gels (Biorad), and proteins were trans-
ferred to PVDF membrane (Millipore, Billerica, MA).
Blots were incubated with anti-CD63 (BD, clone H5C6)
or anti-CD9 (BD, clone M-L13), extensively washed and
then incubated with a goat-anti-mouse (GAM)-horse-
radish peroxidase (Dako, Glostrup, Denmark). Subse-
quently, the PVDF membranes were incubated with a
5-fold diluted peroxidase substrate (LumiLight, Roche
Diagnostics, Almere, The Netherlands) for 5 minutes,
followed by analysis of luminescence using a LAS4000
luminescence image analyser (Fuji, Valhalla, NY).
High density lipoprotein
HDL Cholesterol was determined using the colorimetric
reagent HDL-Cholesterol Plus third generation (Roche
Diagnostics, Almere, The Netherlands) on a Cobas C8000
analyser (Roche) as per manufacturer’s instructions. This
assay specificallydetects HDL-associated cholesterol (21).
Furthermore, a specific protein present in HDL, apo
lipoprotein A1 (APO A1), was measured on an Architect
(Abbott, Abbott Park, IL) according to manufacturer’s
instructions.
Recovery and enrichment
Recovery was defined as the total number of CD61-
exposing vesicles in all fractions combined divided by the
total number of CD61-exposing vesicles in the starting
material. Recovery in a limited number of fractions is the
total number in those fractions divided by the total
number in the starting material.
The enrichment factor of vesicles to protein or HDL in
fraction X is the ratio of CD61-exposing vesicles to
protein or HDL in fraction X compared to the ratio of
vesicles to protein or HDL in the starting material.
Results from 3 independent experiments are presented as
the mean9the standard deviation.
Results
Particles by NTA
The concentration of particles was determined by NTA in
both starting material and fractions. Particles detected by
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settings, NTA will detect single particles with a diameter
larger than 70 nm, which may include not only vesicles,
but also protein aggregates, chylomicrons [size range
1002,000 nm (22)] and very low density lipoproteins
[VLDL; 27200 nm (22)]. NTA will not detect HDL [7
12 nm (22)], low density lipoproteins [LDL; 1823 nm
(22)] and intermediate density lipoproteins [IDL; 2327
nm (22)]. After SEC, the highest concentration of
particles was found in fractions 912 (Fig. 2a). The
recovery of particles measured by NTA was 76%938,
and 46%96 of the recovered particles were present in
fractions 912.
Particles by RPS
The concentration of particles was determined by RPS in
both the starting material and in the fractions. Also
particles detected by RPS are not necessarily vesicles.
With our settings, RPS can detect single particles with a
diameterofapproximately100400nm,whichwillinclude
vesicles, protein aggregates, chylomicrons and VLDL.
RPS will not detect HDL, LDL, or IDL. After SEC, the
highest concentrations of particles were present in frac-
tions912(Fig.2b).Therecoveryofparticlesmeasuredby
RPS was 60%910, and 72%91 of the recovered particles
were present in fractions 912 (Fig. 2b).
Detection of platelet-derived vesicles
Since the particles detected in fractions 912 by both
NTA and RPS are not necessarily vesicles, we applied
flow cytometry to distinguish vesicles from lipoprotein
particles. Because the studied extracellular vesicles origi-
nated from platelets, we used CD61 and lactadherin as
vesicle markers. With our settings, the flow cytometer
detects vesicles with a diameter larger than 500 nm. The
recovery of CD61-exposing vesicles by flow cytometry
was 71%935, and 61%92 of the recovered vesicles were
present in fractions 912 (Fig. 2c, for dot plots see
Supplementary Fig. 1). The recovery of CD61-exposing
vesicles in fractions 912 was 43%923 of the starting
material. The recovery of lactadherin-binding vesicles
was 163%955, and 44%95 of the recovered vesicles were
present in fractions 912 (Fig. 2d). The recovery of
lactadherin-binding vesicles in fractions 912 was 73%
931 of the starting material.
Lipoproteins and protein
The recovery of HDL cholesterol was 103%911, and
fractions 1820 contained 32%92 of total recovered
HDL (Fig. 2e). Although the HDL cholesterol assay is
specific for HDL, we confirmed these measurement
results by also measuring APO A1, a specific HDL
protein, in a control experiment. The recovery of HDL
APO A1 was 72% and fractions 1820 contained 38% of
total recovered HDL APO A1 (Fig. 2f). The recovery of
protein was 95%917, and fractions 1921 contain
36%92 of total recovered protein (Fig. 2g). Fractions
912 contained the majority of vesicles and additionally
contained 4.8%91 of total recovered HDL cholesterol,
whereas HDL APO A1 was below the detection limit
(0.01 g/L) in these fractions. Fractions 912 contained
0.65%90.3 of total recovered protein.
Overview of detected parameters
Figure 2h shows an overlay of the percentage of parti-
cles (NTA, RPS), vesicles (CD61-exposing, lactadherin-
binding), HDL (cholesterol, APO A1) and protein per
fraction. Particles and vesicles showed a peak at fraction
10, whereas HDL (cholesterol and APO A1) and protein
showed a peak at fraction 19 and 20, respectively. Thus, it
is clear that vesicles can be separated from protein and
lipoproteins by SEC.
Presence of proteins per fraction
To directly visualize the efficacy of SEC to separate
vesicles from plasma proteins, a control experiment was
performed in which similar volumes from all collected
fractions (as described in Material and Methods) were
compared for the presence of plasma protein after gel
electrophoresis. The starting material, platelet-free super-
natant of a platelet concentrate (1.5 mL), contained very
high concentrations of proteins including albumin (66
kDa) when applied directly to gel electrophoresis (3 and
20 mL, Fig. 3a, right gel). Evidently, after SEC low levels
of protein become detectable from fraction 8 or 9
onwards, but the bulk of the protein elutes from fraction
15 onwards (Fig. 3a). Thus, vesicles, which are mainly
present in fractions 912, are clearly separated from the
bulk of soluble plasma proteins by SEC.
Presence of CD63 and CD9 per fraction
To confirm the detection of vesicles by flow cytometry,
we performed a control experiment to study the presence
of CD63 and CD9, both vesicle-associated tetraspanins,
by Western blot. CD63 and CD9 were both detectable in
fractions 9 and 10 (Fig. 3b and c, respectively), confirm-
ing the presence of vesicles in these fractions.
Visualization of vesicles, lipoproteins and proteins
TEM was used to confirm the presence of vesicles or
lipoprotein particles. Figure 4 shows representative
images of the starting material and fractions 5, 9, 10,
11, 17, 18, 19 and 20 (Fig. 4ai). In the starting material,
vesicles were not visible due to the abundant presence of
lipoproteins and proteins (Fig. 4a). To improve the
visualization of the contents of the starting material
and fractions 1720, we also performed TEM on 50-fold
diluted samples (Fig. 4jn). In the diluted starting
material, vesicles (cup shaped) as well as lipoproteins
(white spheres) and proteins (white ragged structures)
were visible (Fig. 4j). In fraction 5, no vesicles or
lipoproteins are detectable (Fig. 4b), which confirms the
Anita N. Bo ¨ing et al.
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Citation: Journal of Extracellular Vesicles 2014, 3: 23430 - http://dx.doi.org/10.3402/jev.v3.23430Fig. 2. Presence of vesicles, protein and lipoproteins per fraction. The concentration of vesicles, protein and lipoproteins was
measured in each fraction. Each bar shows the number present in a fraction as % of the total number that passed the column. The height
of the bar represents the mean, the error bars the standard deviation from 3 experiments. a) Particles (larger than 70 nm) measured by
NTA. b) Particles (100400 nm) measured by RPS. c) CD61 vesicles measured by ﬂow cytometry. d) Lactadherinvesicles measured
by ﬂow cytometry. e) HDL (Cholesterol) concentration measured by a colorimetric assay. f) HDL (APOA1) concentration measured by
a turbidimetric assay. g) Protein concentration measured by a Bradford protein assay h) Overview of all measured results.
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Fig. 3. Presence of proteins, CD63 and CD9 in collected fractions. a) The presence of proteins in each fraction determined by loading 20
mL on PAGE gels. The molecular weight of albumin is 66 kDa. b,c) Presence of tetraspanins in the different fractions was studied by
Western blot,with 4 mg proteinused per fraction. First, the presence of CD63 wasshown (53 kDa, panel b), and nextthe presence of CD9
was shown (24 kDa, panel c). The tetraspanin bands areindicated byarrows in panels b and c. Platelet lysate was used as positive control.
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fr. 5
c)
fr. 9
d)
fr. 10
f)
fr. 17
g)
fr. 18
i)
fr. 20
h)
fr. 19
a)
starting material
e)
fr. 11
k)
fr. 17 (50 x)
l)
fr. 18 (50 x)
m)
fr. 19 (50 x)
j)
starting material (50 x)
fr. 20 (50 x)
n)
Fig. 4. TEM images of fractions. Starting material and fractions, undiluted or 50-fold diluted when indicated, were analysed by TEM
for the presence of particles. All images shown are representative images for the starting material (a, j) and fractions 5, 9, 10, 11, 17, 18,
19 and 20 (bi, kn). Scale bar is 200 nm (ag, jn), 500 nm (h), or 1 mm (i).
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fraction 9 the vesicles were clearly visible but also visible
were low numbers of lipoproteins (Fig. 4c). Vesicles were
also visible in fractions 10 and 11 (Fig. 4de), but the
number of lipoprotein particles was increased compared
to fraction 9. The vesicles in fractions 911 range in
diameter from 70 to 500 nm. Very few vesicles and an
abundance of proteins and lipoprotein particles were
visible in fractions 1720 (Fig. 4fi undiluted and 4kn
50-fold diluted). Thus, TEM confirms that SEC separates
vesicles from proteins and lipoproteins.
Recovery and enrichment
As mentioned, most particles and vesicles were present
in fractions 912. To gain insight into the extent of
purification of the vesicles, we calculated the recovery
of CD61-exposing vesicles, protein and HDL cholesterol
of fractions 912 compared to the starting material
(Fig. 5a). In fraction 9, the recovery of vesicles was
14%99andtherecoveriesofproteinandHDLcholesterol
were low, 0.023%90.01 and 0.8%90.07, respectively.
Thus, sepharose CL-2B SEC results in a 5629337-fold
enrichment ofvesicles comparedtoproteins inthestarting
material (Fig. 5b), and a 17911-fold enrichment of
vesicles compared to HDL cholesterol (Fig. 4c).
Whenfractions9and10werecombined,therecoveryof
vesicles was 31%919, but this increase was at the expense
of an increased contamination with protein and HDL
cholesterol compared to fraction 9 alone (Fig. 5a). Never-
theless, combining fractions 9 and 10 gives a 3309111-
fold enrichment of vesicles compared to protein (Fig. 5b),
and a 19911-fold enrichment of vesicles compared to
HDL cholesterol (Fig. 5c). Combining fractions 911 re-
covered 38%921 of the vesicles from the starting material
and results in a 152937-fold enrichment of vesicles
compared to protein (Fig. 5b), and a 1294-fold enrich-
ment of vesicles compared to HDL cholesterol (Fig. 4c).
Combining fractions 912 recovered 43%923 of vesicles
from the starting material and give a 70919-fold enrich-
ment of vesicles compared to protein (Fig. 5b), and a 89
3-fold enrichment of vesicles compared to HDL cholester-
ol(Fig.5c).Thus,itisclearthattherecoveryofvesiclescan
beimprovedbycombiningfractions911or912,butthis
result is at the expense of more contamination by protein
and HDL cholesterol (Fig. 5a).
Discussion
We demonstrate that vesicles can be purified from human
platelet-free supernatant of platelet concentrates by
sepharose CL-2B SEC. With this approach, vesicles can
be easily separated from proteins and HDL. We also
isolated vesicles from human plasma with SEC, which
resulted in similar recoveries of vesicles, proteins and
lipoproteins in fractions 912 (data not shown).
SEC has several major advantages compared to differ-
entialcentrifugationanddensity-gradient ultracentrifuga-
tion, which are the most widely applied protocols for
vesicle isolation. Compared to differential centrifugation,
there is no risk of protein complex formation and vesicle
aggregation. In addition, the high viscosity of plasma
affects the recovery of vesicles isolated by differential
centrifugation (23,24), but does not affect the recovery of
vesicles by SEC.
Compared to density-gradient ultracentrifugation,
buffers with physiological osmolarity and viscosity can
be used. The most commonly applied density gradient for
the isolation of vesicles, sucrose (6,7,2529), may have
some additional downsides. For example, isolation of
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Fig. 5. Recovery and enrichment. The recovery and enrichment
relative to the starting material, in the vesicle-containing
fractions (9, 910, 911, 912) are shown. a) Recovery of
vesicles, protein and HDL (cholesterol) in the vesicle-containing
fractions. b) Enrichment factor of vesicle to protein. c) Enrich-
ment factor of vesicle to HDL (cholesterol).
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is detrimental, since these gradients are ‘‘highly viscous
and grossly hyperosmotic, leading to slow sedimentation
rates for small particles and loss of water from subcellular
organelles’’ (30). Furthermore, whereas several investiga-
tors reported a loss of biological function when vesicles
are isolated by sucrose density-gradient ultracentrifuga-
tion (ISEV meeting Budapest, October 2013), vesicles
from saliva isolated by SEC are still fully functional with
regard to their capacity to induce coagulation (data not
shown, personal communication C.M. Hau), indicating
that the biological properties of vesicles seem unaffected
after isolation by SEC. Moreover, by density-gradient
ultracentrifugation, contaminants with overlapping den-
sities cannot be isolated. For example, the density of
HDL considerably overlaps with vesicles (6,10).
The recovery of vesicles isolated with SEC is 43%923,
when combining fractions 912. Similar recoveries are
reportedafterisolationofvesiclesby(ultra)centrifugation
and detection by flow cytometry, namely 5080% (31).
Furthermore, Momen-Heravi showed a recovery of 2% of
plasma vesicles after ultracentrifugation as measured by
NTA (23). In both studies, however, contamination by
proteins and lipoproteins was not studied. When combin-
ing fractions 912, a reduction of 70-fold in the protein
to vesicle ratio and 8-fold in the HDL to vesicle ratio is
found. To our knowledge, it is unknown to which extent
HDLandproteinarereducedinthevesiclefraction aftera
(sucrose gradient) ultracentrifugation protocol. However,
despite the reduced contamination after isolation of
vesicleswithSEC,werecommendtheuseofbloodsamples
collected from fasting subjects, to minimize potential
contamination by chylomicrons and VLDL.
The principleofSECis separationbasedon adifference
in size. The sepharose beads in the column have poreswith
a diameterof approximately 75 nm (32,33), and atortuous
path through the bead. A particle that can enter the beads
is delayed due to the increased path length. All particles
larger than 75nm, including lipoproteins,cannot enterthe
beadsandcanonlytravelalongwiththevoidvolumefluid.
Based on our TEM results, the smallest vesicles that are
presentinfraction912haveadiameterof70nmorlarger,
which confirms the theoretical separation of components
below and above 75 nm.
Because the size distribution of vesicles, as measured
by RPS and NTA, does not change between the starting
material and fraction 912 (data not shown), there seems
to be no separation of vesicles in the size range from 70 to
500nm. We confirmed this by making a mixture of 100
and 400 nm silica beads. After application of SEC, 45
48% of both sizes of beads were recovered in fractions
912, confirming no separation within this size range
(data not shown).
Vesicles smaller than 75 nm are probably present in the
fractions high in HDL, that is fractions 1820. From the
size distributions of vesicles in urine (34) and erythrocyte
concentrates (Y. Yuana, personal communication), we
estimate that approximately 50% of all vesicles are larger
than 75 nm. It is unknown whether vesicles smaller than
75 nm harbour different clinical information than the
larger vesicles. Sepharose CL-2B has relatively large
pores. Choice of a sepharose with smaller pores may
allow the isolation of vesicles smaller than 75 nm, albeit
with higher contamination by lipoproteins.
We used sepharose CL-2B in a 10 mL plastic syringe
(Fig. 1), which has a diameter of 1.6 cm and a height of
6.2 cm. We expect that the column height, column
diameter and sample volume can be optimized to improve
separation of vesicles from contaminants and the recovery
of vesicles. For example, a longer, narrower column with
the same volume of sepharose may result in an improved
separationofproteinandvesicles.Anarrowercolumnwith
a smaller volume of sepharose and the same length, on the
other hand, may result in a higher recovery of vesicles.
Investigators should optimize those parameters to their
own experimental needs.
Because the size distribution of vesicles does not vary
between fractions 9 and 12, we assume that the vesicles in
each fraction are comparable. Fraction 9 is the purest
vesicle fraction, but contains only 14% of the vesicles in
the starting material. The method used for further
analysis determines whether it is best to collect only
fraction 9 or to combine multiple fractions. For example,
for proteomics the lowest possible contamination with
protein is essential and the use of fraction 9 only may be
optimal. For TEM imaging, the background is much
improved when comparing fractions 911 to the starting
material (Fig. 4ad). Combining multiple fractions may
result in a higher density of vesicles on the TEM grid,
speeding up the analysis. For flow cytometry, we prefer a
higher concentration of vesicles if this does not lead to
swarm detection (35,36), and thus fractions 912 would
be combined.
In conclusion, our study shows that vesicles of a
diameter larger than 75 nm can be isolated from complex
body fluids such as plasma by single-step SEC. Purifica-
tion of vesicles in combined fractions 9-12 relative to
protein and HDL is 70- and 8-fold, respectively. Recovery
of vesicles with sepharose CL-2B SEC is 43% compared
to 280% with ultracentrifugation. Thus, compared to
ultracentrifugation, SEC results in a good recovery of
vesicles with almost complete removal of contaminants.
Furthermore, vesicle isolation by sepharose CL-2B SEC
takes less than 20 minutes, compared to 296 hours for
ultracentrifugation, thus vesicle samples can be prepared
for analysis on the same day of collection. In addition,
sepharose CL-2B SEC components cost approximately
t15,- and no expensive equipment is needed. Thus,
isolation of vesicles by SEC is quick, cheap and easy.
Single-step isolation of extracellular vesicles
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